M. Naesens, D. Kuypers, F. Streit
Nov 1, 2006
Citations
2
Influential Citations
76
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Exposure to mycophenolic acid (MPA) and its main metabolites (MPA 7‐O‐glucuronide [MPAG] and MPA acyl‐glucuronide [AcMPAG]) is characterized by a large interindividual and intraindividual variability, resulting in part from variability in glucuronidation (via uridine diphosphate‐glucuronosyltransferase isoforms) and excretion via multidrug resistance‐associated protein 2 (MRP2). It can be hypothesized that drugs interfering with glucuronidation and excretion will alter (Ac)MPA(G) exposure.